Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2014—Omicia, a genome interpretation company, announced the commercial availability of Opal Clinical, the company’s software-as-a-service solution for diagnostic testing organizations. With Opal Clinical, users can launch NGS tests faster and interpret results more accurately and quickly, the company said in a statement.
December 2014—Aquaro Biosystems introduced its PaceSetter section mounting system, a benchtop instrument that automates the transfer of paraffin-embedded tissue sections directly from microtomes to glass slides.
December 2014—T2 Biosystems received FDA market authorization for its T2Candida Panel and T2Dx Instrument for the direct detection of candida species in human whole blood specimens from patients with symptoms of, or medical conditions predisposing patients to, invasive fungal infections.
December 2014—Sysmex America announced an amended distributorship agreement with Laboratory Supply Co. This agreement is for Sysmex reagents, controls, and instruments, including the Sysmex XS-1000i, Sysmex pocH-100i, Sysmex XP-300, XT-Series, and XN-Series automated hematology analyzers.
December 2014—Thermo Fisher Scientific announced the successful CE-IVD registration of its Ion PGM Dx System for sale in European countries. The system was developed using the Ion Torrent next-generation sequencing technology, currently used in clinical research laboratories to produce tests to uncover meaningful genetic information for a range of human conditions.
December 2014—Roche and ARK Diagnostics announced a distribution agreement that will enable laboratories to integrate ARK’s Methotrexate test into the Roche therapeutic drug monitoring menu for its Cobas c 501 and Cobas c 502 clinical chemistry analyzers.
December 2014—Abbott’s DNA test for the detection of high-risk human papillomavirus is now available in Europe. The test identifies women at increased risk for development of cervical cancer or the presence of high-grade disease.
November 2014—Siemens Healthcare, in agreement with Inpeco, has won an exclusive contract to automate a new, 200,000-square-foot clinical laboratory of Quest Diagnostics in Marlborough, Mass. This will be the first comprehensive automation solution Quest has deployed in one of its regional mega-laboratories in the United States.
November 2014—Eppendorf has launched the Mastercycler Nexus X2, a molecular biology instrument for researchers looking to carry out two PCR reactions simultaneously, without compromising the number of samples.
November 2014—NanoString Technologies announced a highly multiplexed gene expression panel for the nCounter Analysis System, the PanCancer Immune Profiling Panel. The panel will enable researchers to create profiles of the human immune response in all cancer types, potentially accelerating the discovery and development of drugs, therapies, and predictive biomarker signatures for immunotherapy treatment response.
